Cargando…

Radiosensitization by the investigational NEDD8-activating enzyme inhibitor MLN4924 (pevonedistat) in hormone-resistant prostate cancer cells

Salvage radiotherapy (SRT) is the first-line treatment for prostate cancer patients with biochemical recurrence following radical prostatectomy, and new specific radiosensitizers are in urgent need to enhance SRT effect. MLN4924 (also known as Pevonedistat), a specific inhibitor of NEDD8-activating...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wang, Xiaofang, Zhang, Wenjuan, Yan, Zi, Liang, Yupei, Li, Lihui, Yu, Xiaoli, Feng, Yan, Fu, Shen, Zhang, Yanmei, Zhao, Hu, Yu, Jinha, Jeong, Lak Shin, Guo, Xiaomao, Jia, Lijun
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2016
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5122397/ https://www.ncbi.nlm.nih.gov/pubmed/27224919 http://dx.doi.org/10.18632/oncotarget.9526

Ejemplares similares

The Nedd8‐activating enzyme inhibitor MLN4924 (TAK‐924/Pevonedistat) induces apoptosis via c‐Myc‐Noxa axis in head and neck squamous cell carcinoma
por: Zhang, Wenjuan, et al.
Publicado: (2018)

The use of the NEDD8 inhibitor MLN4924 (Pevonedistat) in a cyclotherapy approach to protect wild-type p53 cells from MLN4924 induced toxicity
por: Malhab, Lara J. Bou, et al.
Publicado: (2016)

The NAE inhibitor pevonedistat (MLN4924) synergizes with TNF-α to activate apoptosis
por: Wolenski, F S, et al.
Publicado: (2015)

Pevonedistat (MLN4924): mechanism of cell death induction and therapeutic potential in colorectal cancer
por: Ferris, Jennifer, et al.
Publicado: (2020)

A phase I study of the investigational NEDD8-activating enzyme inhibitor pevonedistat (TAK-924/MLN4924) in patients with metastatic melanoma
por: Bhatia, Shailender, et al.
Publicado: (2016)

MLN4924 (Pevonedistat), a protein neddylation inhibitor, suppresses proliferation and migration of human clear cell renal cell carcinoma
por: Tong, Shuai, et al.
Publicado: (2017)

The p21-Dependent Radiosensitization of Human Breast Cancer Cells by MLN4924, an Investigational Inhibitor of NEDD8 Activating Enzyme
por: Yang, Dong, et al.
Publicado: (2012)

The NEDD8-activating enzyme inhibitor MLN4924 reduces ischemic brain injury in mice
por: Yu, Huilin, et al.
Publicado: (2022)

Effects of the NEDD8-Activating Enzyme Inhibitor MLN4924 on Lytic Reactivation of Kaposi's Sarcoma-Associated Herpesvirus
por: Chang, Pey-Jium, et al.
Publicado: (2017)

An Integrative Pan-Cancer Analysis Revealing MLN4924 (Pevonedistat) as a Potential Therapeutic Agent Targeting Skp2 in YAP-Driven Cancers
por: Lan, Chungen, et al.
Publicado: (2022)

The Nedd8-activating enzyme inhibitor MLN4924 suppresses colon cancer cell growth via triggering autophagy
por: Lv, Yongzhu, et al.
Publicado: (2018)

Mutations in UBA3 Confer Resistance to the NEDD8-Activating Enzyme Inhibitor MLN4924 in Human Leukemic Cells
por: Xu, G. Wei, et al.
Publicado: (2014)

The NEDD8-activating enzyme inhibitor MLN4924 induces G2 arrest and apoptosis in T-cell acute lymphoblastic leukemia
por: Han, Kun, et al.
Publicado: (2016)

Both BRCA1-wild type and -mutant triple-negative breast cancers show sensitivity to the NAE inhibitor MLN4924 which is enhanced upon MLN4924 and cisplatin combination treatment
por: Misra, Shrilekha, et al.
Publicado: (2020)

Correction: Mutations in UBA3 Confer Resistance to the NEDD8-Activating Enzyme Inhibitor MLN4924 in Human Leukemic Cells
Publicado: (2014)

The NEDD8-activating enzyme inhibitor MLN4924 induces DNA damage in Ph+ leukemia and sensitizes for ABL kinase inhibitors
por: Bahjat, Mahnoush, et al.
Publicado: (2019)

Correction for Yu et al., The NEDD8-activating enzyme inhibitor MLN4924 reduces ischemic brain injury in mice
Publicado: (2022)

The Absence of PTEN in Breast Cancer Is a Driver of MLN4924 Resistance
por: Du, Meng-ge, et al.
Publicado: (2021)

Broad and potent antiviral activity of the NAE inhibitor MLN4924
por: Le-Trilling, Vu Thuy Khanh, et al.
Publicado: (2016)

The potential oncogenic and MLN4924-resistant effects of CSN5 on cervical cancer cells
por: Zhang, Huilin, et al.
Publicado: (2021)

Preclinical studies reveal MLN4924 is a promising new retinoblastoma therapy
por: Aubry, Arthur, et al.
Publicado: (2020)

Inhibition of neddylation modification by MLN4924 sensitizes hepatocellular carcinoma cells to sorafenib
por: Yang, Zelong, et al.
Publicado: (2019)

The novel protective role of P27 in MLN4924-treated gastric cancer cells
por: Zhang, Q, et al.
Publicado: (2015)

The Anti-Tumor Activity of the NEDD8 Inhibitor Pevonedistat in Neuroblastoma
por: Foster, Jennifer H., et al.
Publicado: (2021)

The NEDD8-activating enzyme inhibitor MLN4924 sensitizes a TNFR1(+) subgroup of multiple myeloma cells for TNF-induced cell death
por: El-Mesery, Mohamed, et al.
Publicado: (2019)

Neddylation inhibitor MLN4924 suppresses cilia formation by modulating AKT1
por: Mao, Hongmei, et al.
Publicado: (2019)

MLN4924 suppresses neddylation and induces cell cycle arrest, senescence, and apoptosis in human osteosarcoma
por: Zhang, Yi, et al.
Publicado: (2016)

Neddylation inhibitor MLN4924 suppresses growth and migration of human gastric cancer cells
por: Lan, Huiyin, et al.
Publicado: (2016)

Inhibiting Neddylation with MLN4924 Suppresses Growth and Delays Multicellular Development in Dictyostelium discoideum
por: Huber, Robert J., et al.
Publicado: (2021)

MLN4924 inhibits cell proliferation by targeting the activated neddylation pathway in endometrial carcinoma
por: Liu, Huanrong, et al.
Publicado: (2021)

MLN4924 Promotes Self-Renewal of Limbal Stem Cells and Ocular Surface Restoration
por: Li, Qingjian, et al.
Publicado: (2023)

Neddylation inhibitor MLN4924 sensitizes head and neck squamous carcinoma cells to (S)-10-hydroxycamptothecin
por: Gu, Shanshan, et al.
Publicado: (2023)

Cardioprotective effect of MLN4924 on ameliorating autophagic flux impairment in myocardial ischemia-reperfusion injury by Sirt1
por: Zhang, Ji, et al.
Publicado: (2021)

Circadian clock components RORα and Bmal1 mediate the anti-proliferative effect of MLN4924 in osteosarcoma cells
por: Zhang, Shuju, et al.
Publicado: (2016)

MLN4924 Exerts a Neuroprotective Effect against Oxidative Stress via Sirt1 in Spinal Cord Ischemia-Reperfusion Injury
por: Yu, Sifei, et al.
Publicado: (2019)

Celecoxib Synergistically Enhances MLN4924-Induced Cytotoxicity and EMT Inhibition Via AKT and ERK Pathways in Human Urothelial Carcinoma
por: Xiong, Shida, et al.
Publicado: (2022)

Blocking PD1/PDL1 Interactions Together with MLN4924 Therapy is a Potential Strategy for Glioma Treatment
por: Filippova, Natalia, et al.
Publicado: (2018)

The Protein Neddylation Inhibitor MLN4924 Suppresses Patient-Derived Glioblastoma Cells via Inhibition of ERK and AKT Signaling
por: Han, Suji, et al.
Publicado: (2019)

MLN4924 Synergistically Enhances Cisplatin-induced Cytotoxicity via JNK and Bcl-xL Pathways in Human Urothelial Carcinoma
por: Ho, I-Lin, et al.
Publicado: (2015)

The MLN4924 inhibitor exerts a neuroprotective effect against oxidative stress injury via Nrf2 protein accumulation
por: Andérica-Romero, Ana Cristina, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_m2d5qp10u0j7abvl2ot1fcgaa7